Targeted therapeutic approaches for lung cancer, including treatment with TKIs for EGFR or the fusion protein EML4-ALK, have seen substantial progress over the last few years (Sequist et al, 2008; Kwak et al, 2010). Here, ALK is linked to lung cancer.